Sökning: WFRF:(Cars O)
> (2005-2009) >
A population pharma...
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function
-
- Viberg, Anders (författare)
- Uppsala universitet,Avdelningen för farmakokinetik och läkemedelsterapi,Farmakometri
-
- Lannergård, Anders (författare)
- Uppsala universitet,Infektionssjukdomar
-
- Larsson, Anders (författare)
- Uppsala universitet,Klinisk kemi
-
visa fler...
-
- Cars, Otto (författare)
- Uppsala universitet,Infektionssjukdomar
-
- Karlsson, Mats O. (författare)
- Uppsala universitet,Avdelningen för farmakokinetik och läkemedelsterapi,Farmakometri
-
- Sandström, Marie (författare)
- Uppsala universitet,Avdelningen för farmakokinetik och läkemedelsterapi,Farmakometri
-
visa färre...
-
(creator_code:org_t)
- Wiley, 2006
- 2006
- Engelska.
-
Ingår i: British Journal of Clinical Pharmacology. - : Wiley. - 0306-5251 .- 1365-2125. ; 62:3, s. 297-303
- Relaterad länk:
-
https://bpspubs.onli...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims: Since cefuroxime mainly is excreted by renal filtration, dosing is currently based on serum creatinine (Scr) or creatinine clearance (CLcr). However, it has been suggested that cystatin C (CysC) is superior to Scr as a marker of renal function. The aim of this prospective study was to develop a population model that describes the pharmacokinetics of cefuroxime and to investigate the usefulness of CysC as a covariate of the model parameters. Methods: Ninety-seven patients were studied (CLcr range 6.5-115 ml min(-1)). Blood samples (n = 407) for the determination of cefuroxime were withdrawn according to a sparse data sampling schedule and analysed by liquid chromatography mass spectrometry. The population analysis was performed in NONMEM. Results: A two-compartment model described the data well. The biomarkers Scr, CLcr and CysC were evaluated as covariates on clearance (CL). The model that included CysC generated the best fit. In the final population model CL was a function of CysC and body weight, whereas V-1 was only a function of body weight. Final parameter estimates (relative standard errors) were 6.00 (3.2%) l h(-1), 11.4 (5.3%) l and 5.11 (11%) l for CL, V-1 and V-2, respectively. Conclusion: Based on the results of the present study, and because CysC is practical to use in the clinic, it is suggested that individual dosing of cefuroxime may be based on CysC rather than on Scr or CLcr. Furthermore, our final population model may be useful as a tool when designing new dosing schedules for cefuroxime.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Nyckelord
- cefuroxime
- cystatin C
- NONMEM
- pharmacokinetics
- PHARMACY
- FARMACI
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas